WO2009083272A3 - 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL - Google Patents

19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL Download PDF

Info

Publication number
WO2009083272A3
WO2009083272A3 PCT/EP2008/011165 EP2008011165W WO2009083272A3 WO 2009083272 A3 WO2009083272 A3 WO 2009083272A3 EP 2008011165 W EP2008011165 W EP 2008011165W WO 2009083272 A3 WO2009083272 A3 WO 2009083272A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
derivatives
alkyl
saturated
methylene group
Prior art date
Application number
PCT/EP2008/011165
Other languages
English (en)
French (fr)
Other versions
WO2009083272A2 (de
Inventor
Ulrich Klar
Joachim Kuhnke
Rolf Bohlmann
Jan HÜBNER
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009083272(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2710495A priority Critical patent/CA2710495C/en
Priority to ES08867523.6T priority patent/ES2539121T3/es
Priority to EA201000982A priority patent/EA201000982A1/ru
Priority to CN2008801234339A priority patent/CN101910192B/zh
Priority to BRPI0821666-5A priority patent/BRPI0821666A2/pt
Priority to US12/810,860 priority patent/US20100311702A1/en
Priority to JP2010540082A priority patent/JP5600071B2/ja
Priority to EP08867523.6A priority patent/EP2238149B1/de
Priority to NZ586453A priority patent/NZ586453A/en
Priority to AU2008342916A priority patent/AU2008342916A1/en
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of WO2009083272A2 publication Critical patent/WO2009083272A2/de
Publication of WO2009083272A3 publication Critical patent/WO2009083272A3/de
Priority to IL206019A priority patent/IL206019A0/en
Priority to ZA2010/05395A priority patent/ZA201005395B/en
Priority to HK11105768.6A priority patent/HK1151532A1/xx
Priority to US13/738,751 priority patent/US8987239B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die 15α,16α-Methylen-17-hydroxy-19-nor-17-pregna-4-en-3-on-21-carbonsäure γ-Lacton- Derivate der vorliegenden Erfindung besitzen gestagene Wirksamkeit. Sie haben die allgemeine chemische Formel (I), in der Z ausgewählt ist aus der Gruppe, umfassend ein Sauerstoffatom, zwei Wasserstoffatome, NOR und NNHSO2R, worin R Wasserstoff, C1-C10-Alkyl, Aryl oder C7-C20-Aralkyl ist, R4 Wasserstoff oder Halogen ist, ferner entweder: R6a, R6b gemeinsam Methylen oder 1,2-Ethandiyl bilden oder R6a Wasserstoff ist und R6b aus der Gruppe ausgewählt ist, umfassend Wasserstoff, C1-C10-Alkyl, C2-C10-Alkenyl oder C2- C10-Alkinyl, und R7 ausgewählt ist aus der Gruppe, umfassend Wasserstoff, C1-C10-Alkyl, C3-C6-Cycloalkyl, C2-C10-Alkenyl oder C2-C10-Alkinyl, oder: R6a Wasserstoff ist und R6b und R7 gemeinsam eine Bindung, ein Sauerstoff oder Methylen bilden, R18 Wasserstoff oder C1-C3-Alkyl darstellt und umfassen außerdem deren Solvate, Hydrate, Stereoisomere und Salze.
PCT/EP2008/011165 2007-12-29 2008-12-23 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL WO2009083272A2 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP08867523.6A EP2238149B1 (de) 2007-12-29 2008-12-23 19-nor-steroidderivate mit einer 15alpha, 16alpha-methylengruppe und einem gesättigten 17,17-spirolactonring, deren verwendung sowie diese derivate enthaltende arzneimittel
AU2008342916A AU2008342916A1 (en) 2007-12-29 2008-12-23 19-nor-steroid derivatives with a 15alpha,16alpha-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives
NZ586453A NZ586453A (en) 2007-12-29 2008-12-23 19-NOR-STEROID DERIVATIVES WITH A 15alpha,16alpha-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES
CN2008801234339A CN101910192B (zh) 2007-12-29 2008-12-23 具有15α,16α-亚甲基和饱和的17,17-螺内酯环的19-去甲甾类衍生物、其应用以及包含这些衍生物的药物
ES08867523.6T ES2539121T3 (es) 2007-12-29 2008-12-23 Derivados 19-nor-esteroides con un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado, su uso, así como medicamentos que contienen estos derivados
US12/810,860 US20100311702A1 (en) 2007-12-29 2008-12-23 19-nor-steroid derivatives with a 15alpha, 16alpha-methylene group and a saturated 17, 17-spiro-lactone ring, use thereof, and medicaments containing said derivatives
JP2010540082A JP5600071B2 (ja) 2007-12-29 2008-12-23 １５α，１６α−メチレン基及び飽和１７，１７−スピロラクトン環を有する１９−ノル−ステロイド誘導体、その使用及びこれらの誘導体を含む医薬品
CA2710495A CA2710495C (en) 2007-12-29 2008-12-23 19-nor-steroid derivatives with a 15.alpha., 16.alpha.-methylene group and a saturated 17,17-spirolactone ring, use thereof and medicinal products containing these derivatives
EA201000982A EA201000982A1 (ru) 2007-12-29 2008-12-23 19-НОР-СТЕРОИДНЫЕ ПРОИЗВОДНЫЕ С 15α,16α-МЕТИЛЕНОВОЙ ГРУППОЙ И НАСЫЩЕННЫМ 17,17-СПИРОЛАКТОНОВЫМ КОЛЬЦОМ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ ЭТИ ПРОИЗВОДНЫЕ
BRPI0821666-5A BRPI0821666A2 (pt) 2007-12-29 2008-12-23 Derivados 19-nor-esteroides com um grupo 15alfa, 16alfa-metileno e um anel 17, 17-espirolactona saturado, uso deste e produtos medicinais contendo esses derivados
IL206019A IL206019A0 (en) 2007-12-29 2010-05-27 19-NOR-STEROID DERIVATIVES WITH A 15a, 16a-METHYLENE GROUP AND A SATURATED17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES
ZA2010/05395A ZA201005395B (en) 2007-12-29 2010-07-28 19-nor-steroid derivatives with a 15x,16x-methylene group and a saturated 17,17-spirolactone ring,use thereof,and medicaments containing said derivatives
HK11105768.6A HK1151532A1 (de) 2007-12-29 2011-06-08
US13/738,751 US8987239B2 (en) 2007-12-29 2013-01-10 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007063495.3 2007-12-29
DE102007063495A DE102007063495A1 (de) 2007-12-29 2007-12-29 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/810,860 A-371-Of-International US20100311702A1 (en) 2007-12-29 2008-12-23 19-nor-steroid derivatives with a 15alpha, 16alpha-methylene group and a saturated 17, 17-spiro-lactone ring, use thereof, and medicaments containing said derivatives
US13/738,751 Continuation US8987239B2 (en) 2007-12-29 2013-01-10 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives

Publications (2)

Publication Number Publication Date
WO2009083272A2 WO2009083272A2 (de) 2009-07-09
WO2009083272A3 true WO2009083272A3 (de) 2009-08-27

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/011165 WO2009083272A2 (de) 2007-12-29 2008-12-23 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL

Country Status (26)

Country Link
US (2) US20100311702A1 (de)
EP (1) EP2238149B1 (de)
JP (1) JP5600071B2 (de)
KR (1) KR20100102136A (de)
CN (1) CN101910192B (de)
AR (1) AR069962A1 (de)
AU (1) AU2008342916A1 (de)
BR (1) BRPI0821666A2 (de)
CA (1) CA2710495C (de)
CL (1) CL2008003919A1 (de)
CO (1) CO6290675A2 (de)
DE (1) DE102007063495A1 (de)
DO (1) DOP2010000199A (de)
EA (1) EA201000982A1 (de)
EC (1) ECSP10010315A (de)
ES (1) ES2539121T3 (de)
HK (1) HK1151532A1 (de)
IL (1) IL206019A0 (de)
NZ (1) NZ586453A (de)
PA (1) PA8810701A1 (de)
PE (1) PE20091336A1 (de)
TW (1) TW200940074A (de)
UA (1) UA98834C2 (de)
UY (1) UY31580A1 (de)
WO (1) WO2009083272A2 (de)
ZA (1) ZA201005395B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150157A2 (de) * 1984-01-20 1985-07-31 Schering Aktiengesellschaft 6,6-Ethylen-15,16-methylen-3-oxo-17alpha-pregn-4-en-21,17-carbolactone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Prâparate
WO2006072467A1 (de) * 2004-12-30 2006-07-13 Schering Aktiengesellschaft 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150157A2 (de) * 1984-01-20 1985-07-31 Schering Aktiengesellschaft 6,6-Ethylen-15,16-methylen-3-oxo-17alpha-pregn-4-en-21,17-carbolactone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Prâparate
WO2006072467A1 (de) * 2004-12-30 2006-07-13 Schering Aktiengesellschaft 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANDEMIRLI FATMA ET AL: "Investigation of structure-activity relationship on 17-spirolactone derivatives: the electronic-topological approach", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 57, no. 7, 1 July 2002 (2002-07-01), pages 601 - 607, XP002418597, ISSN: 0014-827X *

Also Published As

Publication number Publication date
CN101910192A (zh) 2010-12-08
DE102007063495A1 (de) 2009-09-17
DOP2010000199A (es) 2010-10-15
CO6290675A2 (es) 2011-06-20
UA98834C2 (ru) 2012-06-25
JP5600071B2 (ja) 2014-10-01
US8987239B2 (en) 2015-03-24
PA8810701A1 (es) 2009-12-16
PE20091336A1 (es) 2009-10-04
KR20100102136A (ko) 2010-09-20
EA201000982A1 (ru) 2011-02-28
NZ586453A (en) 2012-05-25
JP2011507928A (ja) 2011-03-10
UY31580A1 (es) 2009-08-03
WO2009083272A2 (de) 2009-07-09
AU2008342916A1 (en) 2009-07-09
US20100311702A1 (en) 2010-12-09
HK1151532A1 (de) 2012-02-03
EP2238149A2 (de) 2010-10-13
CN101910192B (zh) 2013-07-31
CA2710495A1 (en) 2009-07-09
IL206019A0 (en) 2010-11-30
EP2238149B1 (de) 2015-03-18
TW200940074A (en) 2009-10-01
CA2710495C (en) 2015-04-28
ECSP10010315A (es) 2010-08-31
AR069962A1 (es) 2010-03-03
ZA201005395B (en) 2012-01-25
CL2008003919A1 (es) 2010-05-07
US20130123219A1 (en) 2013-05-16
BRPI0821666A2 (pt) 2015-06-16
ES2539121T3 (es) 2015-06-26

Similar Documents

Publication Publication Date Title
MX2009013626A (es) DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE.
RS20060041A (en) Carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
EP1775289A4 (de) Neue imidazolidinderivate
MX2009010024A (es) Nuevo compuesto de adenina.
TN2010000091A1 (en) Substituted pyrazole derivative
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
WO2009116067A3 (en) Novel derivatives of acyl cyanopyrrolidines
MY139461A (en) Condensed furan compounds
MY155015A (en) 18- methyl-19-norandrost-4-ene-17,17 spiro ether (18-methyl-19-nor-20- spirox -4-en-3-one), and pharmaceutical products comprising the same
MX2010003576A (es) Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
NZ596653A (en) Total synthesis of salinosporamide a and analogs thereof
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
WO2009083272A3 (de) 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL
EP0997462A4 (de) Naphthyridinderivate oder salze davon
BR0308759A (pt) Derivados de fenil amidas siliconadas utilizáveis como microbiocida
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
MX2009013629A (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO.
MY161992A (en) Novel tetrahydroisoquinoline derivative
MX2009013631A (es) DERIVADO DE 17ß-CIANO-19-ANDROST-4-ENO, SU USO Y MEDICAMENTOS QUE COMPRENDEN AL DERIVADO.
MX2010000001A (es) Derivados de naftaleno novedoso, proceso para la preparacion de los mismos y composiciones farmaceuticas que contienen los mismos.
TW200716112A (en) Benzimidazole compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880123433.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867523

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008867523

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 206019

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12010501303

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 4234/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2710495

Country of ref document: CA

Ref document number: 2008342916

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 586453

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20107014303

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010540082

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10078685

Country of ref document: CO

Ref document number: 201011540

Country of ref document: CR

Ref document number: D2010137

Country of ref document: CU

Ref document number: MX/A/2010/007272

Country of ref document: MX

Ref document number: CR2010-011540

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201000982

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2008342916

Country of ref document: AU

Date of ref document: 20081223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010002950

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: A201009129

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 12810860

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0821666

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100629